The definition of primary and secondary glioblastoma.
Ohgaki H, Kleihues P.
Clin Cancer Res. 2013 Feb 15;19(4):764-72. doi: 10.1158/1078-0432.CCR-12-3002. Epub 2012 Dec 3.
Perioperative Management of Patients with Glioblastoma.
De Biase G, Garcia DP, Bohnen A, Quiñones-Hinojosa A.
Neurosurg Clin N Am. 2021 Jan;32(1):1-8. doi: 10.1016/j.nec.2020.09.005. Epub 2020 Nov 5.
Shaping the glioblastoma microenvironment to enhance CAR-NK immunotherapy.
Tang E, Chen JY.
Front Immunol. 2025 Dec 1;16:1681966. doi: 10.3389/fimmu.2025.1681966. eCollection 2025.
Optimizing glioblastoma resection: intraoperative mapping and beyond.
Osorio JA, Aghi MK.
CNS Oncol. 2014;3(5):359-66. doi: 10.2217/cns.14.36.
A comprehensive profile of recurrent glioblastoma.
Campos B, Olsen LR, Urup T, Poulsen HS.
Oncogene. 2016 Nov 10;35(45):5819-5825. doi: 10.1038/onc.2016.85. Epub 2016 Apr 4.
Glioblastoma microenvironment contains multiple hormonal and non-hormonal growth-stimulating factors.
Dahlberg D, Rummel J, Distante S, De Souza GA, Stensland ME, Mariussen E, Rootwelt H, Voie Ø, Hassel B.
Fluids Barriers CNS. 2022 Jun 4;19(1):45. doi: 10.1186/s12987-022-00333-z.
Molecular biology of glioblastoma: Classification and mutational locations.
Soomro SH, Ting LR, Qing YY, Ren M.
J Pak Med Assoc. 2017 Sep;67(9):1410-1414.
Glioblastoma metastases: a literature review and a description of six clinical observations.
Goryaynov SA, Potapov AA, Ignatenko MA, Zhukov VY, Protskiy SV, Zakharova NA, Okhlopkov VA, Shishkina LV.
Zh Vopr Neirokhir Im N N Burdenko. 2015;79(2):33-43. doi: 10.17116/neiro201579233-43.
The potential of advanced MR techniques for precision radiotherapy of glioblastoma.
Tang PLY, Méndez Romero A, Jaspers JPM, Warnert EAH.
MAGMA. 2022 Feb;35(1):127-143. doi: 10.1007/s10334-021-00997-y. Epub 2022 Feb 7.
Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
Takano S.
Brain Tumor Pathol. 2012 Apr;29(2):73-86. doi: 10.1007/s10014-011-0077-6. Epub 2012 Jan 6.
